Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235989 · ClinicalTrials.gov registry record · Phase 2
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 17
- Study locations
NCT00235989: Completed Phase 2 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bayer.
NCT00235989 is a Phase 2 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Bayer. The registered enrollment target is 63 participants, below the 560-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (89% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00235989, a Phase 2 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.
Primary Outcome
Outcome measures are given as the number of patients with common toxicity by the Common Toxicity Criteria (CTC). Toxicity grading is: Grade 1: no study drug action recommended, Grade 2: Dose reduction or interruption of study treatment should be considered (grade 2 Lymphocyte toxicity required no study drug action), Grade 3: Dose reduction or interruption should be considered; interruption is recommended, and Grade 4: Interruption of study drug is recommended (Grade 4 laboratory toxicity was rep
Conditions Studied
Interventions
- DRUG Interferon beta 1b (Betaseron, BAY86-5046)
Study Locations (17)
North Carolina
- - Durham
- - High Point
- - Winston-Salem
California
- - Los Angeles
- - San Francisco
Michigan
- - Ann Arbor
- - Ann Arbor
Tennessee
- - Nashville
- - Nashville
District of Columbia
- - Washington D.C.
Georgia
- - Atlanta
Illinois
- - Chicago
Kansas
- - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
What the finished NCT00235989 record still lists
NCT00235989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 560-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Interferon beta 1b (Betaseron, BAY86-5046) is the first listed.
NCT00235989 lists 17 locations in 12 states (North Carolina, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT00235989 about?
NCT00235989 is a clinical study titled "Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis". The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.
What is the current status of trial NCT00235989?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2003-06. Estimated completion is 2008-01.
What conditions does trial NCT00235989 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT00235989?
The interventions under investigation include: Interferon beta 1b (Betaseron, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00235989?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00235989 being conducted?
This trial has 17 study locations across California, District of Columbia, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00235989's enrollment target sits among peer trials
63 19th of 29 higher than 11 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
COMPLETED · Phase 2
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
MS-ResearchBiomarkerS
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia